DeVore Adam D, Milano Carmelo A, Rogers Joseph G
1 Duke Clinical Research Institute, 2 Department of Medicine, 3 Division of Cardiothoracic Surgery, Duke University School of Medicine, Durham, NC 27715, USA.
Ann Cardiothorac Surg. 2014 Nov;3(6):603-5. doi: 10.3978/j.issn.2225-319X.2014.08.22.
The past five years have seen remarkable growth in the use of durable, continuous flow left ventricular assist devices (LVAD) with associated improvements in mortality, quality of life, functionality and end-organ function. To sustain the growth of this important therapy, the LVAD community must now address key issues focused around the costs of LVAD care, refined patient selection, and reducing complications associated with this therapy. In this perspective piece, we discuss many of these issues.
在过去五年中，耐用的连续血流左心室辅助装置（LVAD）的使用显著增加，患者的死亡率、生活质量、功能和终末器官功能也随之改善。为了维持这一重要治疗方法的发展，LVAD领域现在必须解决一些关键问题，这些问题主要围绕LVAD治疗的成本、优化患者选择以及减少与该治疗相关的并发症。在这篇观点文章中，我们将讨论其中的许多问题。
